352. Chris Kiple, CEO of Solius Labs

Today, I'm joined by Chris Kiple, CEO of Solius Labs.

 

A decade in development, Solius's FDA-cleared UVB light therapy device personalizes dosage by skin type, aiming to replicate the benefits of sunlight while minimizing carcinogenic risk. 

 

In this episode, we discuss sunlight as a foundational pillar of health and longevity. 

 

We also cover:

• Why sun avoidance is deadlier than smoking
• Designing a skin scanner for personalized UVB dosing
• Moving UVB therapy from clinical dermatology to consumer health

Subscribe to the podcast → insider.fitt.co/podcast 

Subscribe to our newsletter → insider.fitt.co/subscribe 

Follow us on LinkedIn → linkedin.com/company/fittinsider 

 

Website: www.solius.com 

Instagram: https://www.instagram.com/soliuslabs 

 

-

 

The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com  to learn more about its smart fitness ecosystem for fitness and health facilities.

 

Fitt Talent: https://talent.fitt.co/ 

Consulting: https://consulting.fitt.co/ 

Investments: https://capital.fitt.co/ 

 

Chapters:

(00:00) Introduction

(00:29) Swedish longevity study

(01:20) Chris background and Solius overview

(02:05) UVB light therapy foundation

(04:00) 10-year development and timing

(05:07) Sun exposure evolution and skin type

(08:10) Solius technology and personalized dosing

(09:35) Skin scanning and dosing mechanism

(11:00) FDA clearance and safety focus

(12:40) OTC vs. prescription positioning

(14:15) Safety risk contextualization

(15:42) Healthcare partnerships strategy

(17:50) Dermatology focus

(19:00) Orthopedic and cardiovascular applications

(20:32) Longevity clinic partnerships

(22:35) Swedish and UK biobank studies

(26:00) Hormone production benefits

(27:20) Cardiovascular and nitric oxide improvements

(28:30) Microbiome diversity impact

(31:15) Platform evolution and future devices

(33:20) Team-building and advisory board

(34:45) Listening to early users

(36:40) Where to find

(38:07) Conclusion